Companies: 49,246 Total Market Cap: 132441797263938.02

Fagron NV

EBR-FAGR
Healthcare Drug Manufacturers - Specialty & Generic
Rank #6625
Market Cap 1.72 B
Volume 23,815
Price 24.03
Change (%) 1.91%
Country or region Belgium Belgium

Fagron NV's latest marketcap:

1.72 B

As of 05/20/2025, Fagron NV's market capitalization has reached $1.72 B. According to our data, Fagron NV is the 6625th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 1.72 B
Revenue (ttm) 981.23 M
Net Income (ttm) 90.65 M
Shares Out 72.84 M
EPS (ttm) 1.24
Forward PE 15.47
Ex-Dividend Date 05/19/2025
Earnings Date 07/31/2025
Market Cap Chart
Data Updated: 05/20/2025

Fagron NV's yearly market capitalization.

Fagron NV has seen its market value grow from €1.38 B to €1.53 B since 2020, representing a total increase of 10.97% and an annual compound growth rate (CAGR) of 2.40%.
Date Market Cap Change (%)
05/20/2025 €1.53 B 26.83%
12/31/2024 €1.22 B 0.84%
12/29/2023 €1.21 B 25.41%
12/30/2022 €967.24 M -10.3%
12/31/2021 €1.08 B -21.59%
12/31/2020 €1.38 B

Company Profile

About Fagron NV

Fagron NV is a pharmaceutical compounding company dedicated to delivering personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.

Business Segments

The company operates through three key segments:

  • Essentials
  • Brands
  • Compounding Services

Key Products & Services

  • DiluCap – A line of excipients for compounding capsule formulations.
  • Imuno TF Complex – Supports immune response regulation.
  • Pigmerise – A natural phytocomplex for hypopigmentation disorders like vitiligo.
  • Pentravan – Used to avoid first-pass metabolism and prevent gastrointestinal erosion.
  • Nourisil MD – A first-line therapy for scar and keloid prevention and treatment.
  • Neogen – A specialized line of hair care products.
  • TrichoConcept – Designed for alopecia treatment.
  • Fagron Advanced Derma – Provides skincare, compounded treatments, and personalized dermatological care.
  • SyrSpend SF – Ensures pharmaceutical stability, dosage consistency, and patient comfort.
  • Cleoderm – A topical cream for personalized dermatological treatments.

Education & Development

Fagron NV also supports the professional development of prescribers and pharmacists through its Fagron Academy.

Company Background

Originally founded in 1990 as Arseus NV, the company rebranded to Fagron NV in January 2015. It is headquartered in Nazareth, Belgium.

Frequently Asked Questions

As of 05/20/2025, Fagron NV (including the parent company, if applicable) has an estimated market capitalization of $1.72 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Fagron NV global market capitalization ranking is approximately 6625 as of 05/20/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region Belgium
Founded 1990
IPO Date n/a
Employees 3,828
CEO Rafael Padilla
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Address Venecoweg 20A
Nazareth, 9810
Belgium
Website https://www.fagron.com